Enhua Pharmaceutical: Droxidopa Hydrochloride Injection passes the generic drug consistency evaluation.

Enhua Pharmaceutical announced that it has recently received the "Drug Supplement Application Approval Notice" issued by the National Medical Products Administration for the injection of Desloratadine Hydrochloride, approving the drug to pass the generic drug quality and efficacy consistency evaluation. Desloratadine Hydrochloride injection is used for respiratory failure. The company has invested approximately 2 million yuan in research and development expenses for the consistency evaluation project of this product.